Clinical Trial Update: N-of-1 for Beta-Blockers in Cardiac Amyloidosis [Phase 4]

View source ↗

Summary

An N-of-1 trial evaluating beta-blockers for cardiac amyloidosis is currently enrolling by invitation in Phase 4.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiac Amyloidosis
• Transthyretin-related Cardiac Amyloidosis

Drugs mentioned

• Beta blockers (class) (beta-adrenergic blockers)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Cardiac Amyloidosis, Heart Diseases | Phase 4 | Status: ENROLLING_BY_INVITATION